The study will evaluate the efficacy and safety of obinutuzumab in patients with advanced non-pretreated follicular lymphoma (LF) undergoing treatment with obinutuzumab as part of routine clinical practice, measured by the percentage of patients who relapsed in 24 months following the start of treatment (POD24).
https://andro.io/app/urban-project
Power 100
Android app profile
Urban ePRO for Android – Latest Version & Features
★★★★★
(0 ratings)
Rate this app
How do you feel about Urban ePRO?
Thanks for your feedback!
> 2.2k
Monthly Downloads
~$900
Estimated Cost
Screenshots
